Sagimet Biosciences Inc.
SGMT
$10.55
$1.2713.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -31.01% | -11.31% | 25.88% | -24.28% | 42.86% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 113.64% | -14.30% | 0.05% | 43.76% | 44.47% |
| Change in Net Operating Assets | -385.38% | 107.01% | -712.41% | 660.80% | -104.69% |
| Cash from Operations | -28.89% | 27.23% | -16.24% | -11.86% | 37.39% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -335.12% | -28.85% | 19,044.00% | 100.56% | -489.39% |
| Cash from Investing | -335.12% | -28.85% | 19,044.00% | 100.56% | -489.39% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | 27,300.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -100.00% | 27,300.00% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7,954.21% | -36.44% | 125.68% | 56.09% | -101.29% |